BR9712518A - Polipeptìdeo, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processo para detectar tuberculose em um paciente, e, kit diagnóstico - Google Patents

Polipeptìdeo, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processo para detectar tuberculose em um paciente, e, kit diagnóstico

Info

Publication number
BR9712518A
BR9712518A BR9712518-0A BR9712518A BR9712518A BR 9712518 A BR9712518 A BR 9712518A BR 9712518 A BR9712518 A BR 9712518A BR 9712518 A BR9712518 A BR 9712518A
Authority
BR
Brazil
Prior art keywords
vaccine
polypeptide
patient
fusion protein
expression vector
Prior art date
Application number
BR9712518-0A
Other languages
English (en)
Inventor
Steven G Reed
Yasir A W Skeiky
Davin C Dillon
Antonio Campos-Neto
Raymond Houghton
Thomas S Vedvick
Daniel R Twardzik
Michael J Lodes
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of BR9712518A publication Critical patent/BR9712518A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"POLIPEPTìDEO, MOLéCULA DE DNA, VETOR DE EXPRESSãO, CéLULA HOSPEDEIRA, COMPOSIçãO FARMACêUTICA, VACINA, PROTEìNA DE FUSãO, PROCESSO PARA DETECTAR TUBERCULOSE EM UM PACIENTE, E, KIT DIAGNóSTICO" Compostos e processos para induzir uma imunidade protetora contra tuberculose são descritos. Os compostos providos incluem polipeptídeos que contém pelo menos uma porção imunogênica de uma ou mais proteínas de M. tuberculosis e moléculas de DNA codificando estes polipeptídeos. Estes compostos podem ser formulados em vacinas e/ou composições farmacêuticas para imunização contra infecção por M. tuberculosis, ou podem ser usados para o diagnóstico de tuberculose.
BR9712518-0A 1996-10-11 1997-10-07 Polipeptìdeo, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processo para detectar tuberculose em um paciente, e, kit diagnóstico BR9712518A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73051096A 1996-10-11 1996-10-11
US08/818,112 US6290969B1 (en) 1995-09-01 1997-03-13 Compounds and methods for immunotherapy and diagnosis of tuberculosis
PCT/US1997/018293 WO1998016646A2 (en) 1996-10-11 1997-10-07 Compounds and methods for immunotherapy and diagnosis of tuberculosis

Publications (1)

Publication Number Publication Date
BR9712518A true BR9712518A (pt) 2000-10-24

Family

ID=27112065

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712518-0A BR9712518A (pt) 1996-10-11 1997-10-07 Polipeptìdeo, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processo para detectar tuberculose em um paciente, e, kit diagnóstico

Country Status (14)

Country Link
US (3) US6290969B1 (pt)
EP (1) EP0932681A2 (pt)
JP (1) JP2001501832A (pt)
KR (1) KR20000049101A (pt)
AU (1) AU4814497A (pt)
BR (1) BR9712518A (pt)
CA (1) CA2268008A1 (pt)
CZ (1) CZ126599A3 (pt)
IL (1) IL129388A0 (pt)
NO (1) NO991694L (pt)
PL (1) PL332878A1 (pt)
TR (1) TR199901571T2 (pt)
WO (1) WO1998016646A2 (pt)
ZA (1) ZA978969B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6991797B2 (en) 1993-07-02 2006-01-31 Statens Serum Institut M. tuberculosis antigens
US6015681A (en) * 1995-07-28 2000-01-18 The United States Of America As Represented By The Secretary Of The Navy Rapid immunoassay for cariogenic bacteria
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6982085B2 (en) 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
US6555653B2 (en) * 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
CA2296419A1 (en) * 1997-07-16 1999-01-28 Institut Pasteur A polynucleotide functionally coding for the lhp protein from mycobacterium tuberculosis, its biologically active derivative fragments, as well as methods using the same
EP1484405A1 (en) * 1997-11-10 2004-12-08 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from M. Tuberculosis
EP1787994A1 (en) 1998-10-08 2007-05-23 Statens Serum Institut TB vaccine and diagnostic based on antigens from M. tuberculosis cell
AU766093B2 (en) * 1998-10-08 2003-10-09 Statens Serum Institut Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell
DE69941545D1 (de) 1998-11-04 2009-11-26 Isis Innovation Tuberkulose diagnose test
AU2594500A (en) * 1998-12-24 2000-07-31 Corixa Corporation Methods for using mycobacterium tuberculosis molecules as immunological adjuvants
WO2000047227A2 (en) * 1999-02-09 2000-08-17 Powderject Vaccines, Inc. Mycobacterium tuberculosis, immunization
US20030027774A1 (en) * 1999-03-18 2003-02-06 Ronald C. Hendrickson Tuberculosis antigens and methods of use therefor
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
EP1214088B1 (en) 1999-05-04 2009-04-22 The University of Medicine and Dentistry of New Jersey Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines
WO2001024820A1 (en) 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US6316205B1 (en) 2000-01-28 2001-11-13 Genelabs Diagnostics Pte Ltd. Assay devices and methods of analyte detection
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
SI1542732T1 (sl) * 2000-06-20 2010-01-29 Corixa Corp Csc The United Sta Fuzijski proteini Mycobacterium tuberculosis
FR2818647B1 (fr) * 2000-12-21 2006-09-29 Pasteur Institut Glycopeptides immunogenes, criblage, preparation et applications
EP1463526A4 (en) * 2001-08-02 2006-08-30 Univ New York EARLY DETECTION OF MYCOBACTERIAL DISEASES USING PEPTIDES
US7026465B2 (en) * 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
ITRM20040091A1 (it) * 2004-02-19 2004-05-19 Istituto Naz Per Le Malattie Test immunologico rapido per la diagnosi ed il monitoraggio dell'infezione tubercolare.
US7820142B2 (en) 2004-09-30 2010-10-26 Institut Pasteur Immunogenic glycopeptides, screening, preparation and uses
US8475735B2 (en) * 2004-11-01 2013-07-02 Uma Mahesh Babu Disposable immunodiagnostic test system
SG159555A1 (en) * 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
ATE543832T1 (de) 2005-04-29 2012-02-15 Glaxosmithkline Biolog Sa Verfahren zur vorbeugung oder behandlung einer m.-tuberculosis-infektion
CN101365714A (zh) 2005-07-01 2009-02-11 福赛特儿童口腔医院 结核抗原的检测分析及疫苗
WO2007041539A1 (en) 2005-09-30 2007-04-12 Transcutaneous Technologies, Inc. Iontophoresis apparatus and method for the diagnosis of tuberculosis
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
EP2368568A1 (en) 2006-11-01 2011-09-28 Immport Therapeutics, INC. Compositions and methods for immunodominant antigens
KR20120129927A (ko) 2010-01-27 2012-11-28 글락소 그룹 리미티드 변형된 투베르쿨로시스 항원
EP2573107A1 (en) * 2011-09-21 2013-03-27 Norwegian Institute of Public Health A recombinant fusion protein
FR3048286B1 (fr) * 2016-02-26 2021-01-22 Omunis Peptides immunogenes et leur utilisation

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US533754A (en) * 1895-02-05 Elliott j
AU5856073A (en) 1973-06-28 1975-01-30 Toru Tsumits Tuberculin active proteins and peptides
FR2244539A1 (en) * 1973-07-13 1975-04-18 Mitsui Pharmaceuticals Tuberculin active proteins and peptides prepn - from tubercle bacillus
FR2265402A1 (en) * 1974-03-29 1975-10-24 Mitsui Pharmaceuticals Tuberculin active proteins and peptides prepn - from tubercle bacillus
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4876089A (en) * 1984-09-06 1989-10-24 Chiron Corporation Feline leukemia virus protein vaccines
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4689397A (en) 1985-08-12 1987-08-25 Scripps Clinic And Research Foundation Synthetic polypeptides for detecting mycobacterial infections
US4777127A (en) * 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4879213A (en) 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
AU1548388A (en) 1987-02-02 1988-08-24 Whitehead Institute For Biomedical Research Mycobacterium tuberculosis genes and encoding protein antigens
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4952395A (en) 1987-02-26 1990-08-28 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US4976958A (en) 1987-02-26 1990-12-11 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US5504005A (en) * 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5108745B1 (en) 1988-08-16 1998-06-30 Univ California Tuberculosis and legionellosis vaccines and methods for their production
US5549910A (en) * 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
EP0419355B1 (en) 1989-09-19 2000-02-09 N.V. Innogenetics S.A. Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis
ATE189684T1 (de) 1989-09-19 2000-02-15 Innogenetics Nv Rekombinante polypeptide und peptide, dafür kodierende nukleinsäuren und ihre verwendung in der tuberkulose-diagnose
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
SE9001105D0 (sv) 1990-03-27 1990-03-27 Astra Ab New methods foer diagnosis of tuberculosis
US5466468A (en) * 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
JP3218637B2 (ja) * 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
EP0503055A1 (en) 1990-09-06 1992-09-16 Rijksuniversiteit Utrecht Inhibitor of lymphocyte response and immune-related disease
ATE154759T1 (de) * 1990-11-08 1997-07-15 Univ London Mycobacterium als adjuvans für antigene
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP0499003A1 (en) 1991-02-14 1992-08-19 N.V. Innogenetics S.A. Polypeptides and peptides, particularly recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnosis of tuberculosis
ES2152928T3 (es) 1991-03-25 2001-02-16 Innogenetics Nv Polipeptidos de mycobacterium paratuberculosis.
RU2024021C1 (ru) 1991-05-05 1994-11-30 Научно-исследовательский институт хирургии Восточно-Сибирского филиала СО РАМН Способ диагностики туберкулеза
DE4116249A1 (de) 1991-05-17 1992-11-19 Biotechnolog Forschung Gmbh Hybrid-plasmid fuer m.-tuberculosis-antigen, e. coli als wirt und antigen
GB9111291D0 (en) 1991-05-24 1991-07-17 Medical Res Council Diagnostic peptides
FR2677365B1 (fr) 1991-06-07 1995-08-04 Pasteur Institut Proteines de mycobacterium et applications.
US5240856A (en) * 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
DE69312487T2 (de) * 1992-05-18 1997-11-27 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5330754A (en) 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
NL9202197A (nl) * 1992-12-17 1994-07-18 Kreatech Biotech Bv Werkwijze en inrichting voor het identificeren van een voor een mycobacteriële infectie verantwoordelijk mycobacterium species.
US5928647A (en) * 1993-01-11 1999-07-27 Dana-Farber Cancer Institute Inducing cytotoxic T lymphocyte responses
US5616500A (en) * 1993-04-30 1997-04-01 The United States Of America As Represented By The Department Of Health & Human Services Trichohyalin and transglutaminase-3 and methods of using same
US5955077A (en) * 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
DK79893D0 (da) 1993-07-02 1993-07-02 Statens Seruminstitut New vaccine
DK79793D0 (da) 1993-07-02 1993-07-02 Statens Seruminstitut Diagnostic test
US5639653A (en) * 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
JPH09505588A (ja) 1993-11-23 1997-06-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 多くの細胞外生成物及びそれらの製造法並びに使用
GB9409985D0 (en) 1994-05-18 1994-07-06 Medical Res Council Vaccine against mycobacterial infections
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
DE4446509A1 (de) * 1994-12-24 1996-06-27 Sel Alcatel Ag Verfahren zur Herstellung von Leiterbahnen auf einem Vertiefungen aufweisenden Substrat
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5714593A (en) * 1995-02-01 1998-02-03 Institut Pasteur DNA from mycobacterium tuberculosis which codes for a 45/47 kilodalton protein
US5580579A (en) * 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
AU706367B2 (en) 1995-03-13 1999-06-17 Astra Aktiebolag New DNA molecules
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6338852B1 (en) * 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
WO1997009429A2 (en) * 1995-09-01 1997-03-13 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
DE69637879D1 (de) * 1995-09-01 2009-04-30 Corixa Corp Verbindungen und Verfahren zur Immuntherapie und Diagnose von Tuberkulose
US6458366B1 (en) * 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
BR9708082A (pt) * 1996-03-15 1999-07-27 Corixa Corp Compostos e métodos para a imunoterapia e imunodiagnose de câncer de próstata
US5985287A (en) * 1996-08-29 1999-11-16 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6544522B1 (en) * 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6350456B1 (en) * 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US6627198B2 (en) * 1997-03-13 2003-09-30 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis antigens and their uses
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6355257B1 (en) * 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6555653B2 (en) * 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
CN1163602C (zh) * 1998-04-07 2004-08-25 科里克萨公司 结核杆菌抗原融合蛋白及其应用
US6465633B1 (en) * 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
SI1542732T1 (sl) * 2000-06-20 2010-01-29 Corixa Corp Csc The United Sta Fuzijski proteini Mycobacterium tuberculosis
US7026465B2 (en) * 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis

Also Published As

Publication number Publication date
AU4814497A (en) 1998-05-11
CZ126599A3 (cs) 1999-11-17
WO1998016646A2 (en) 1998-04-23
NO991694D0 (no) 1999-04-09
US20110305721A1 (en) 2011-12-15
US20090017077A1 (en) 2009-01-15
CA2268008A1 (en) 1998-04-23
IL129388A0 (en) 2000-02-17
WO1998016646A3 (en) 1998-10-08
JP2001501832A (ja) 2001-02-13
TR199901571T2 (xx) 1999-10-21
EP0932681A2 (en) 1999-08-04
US7989605B2 (en) 2011-08-02
ZA978969B (en) 1998-04-20
US6290969B1 (en) 2001-09-18
PL332878A1 (en) 1999-10-25
KR20000049101A (ko) 2000-07-25
NO991694L (no) 1999-06-10

Similar Documents

Publication Publication Date Title
BR9712518A (pt) Polipeptìdeo, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processo para detectar tuberculose em um paciente, e, kit diagnóstico
BR9809445A (pt) Polipeptìdeo compreendendo uma porção imunogênica de um antìgeno de m. tubercolosis, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processos para indução de imunidade protetora em um paciente, processo de detecção de tuberculose em um paciente,e , kit de diagnóstico.
BR9916020A (pt) Compostos e métodos para o tratamento e diagnóstico de infecção por chlamydia
Montelaro et al. Antigenic variation during persistent infection by equine infectious anemia virus, a retrovirus.
Gotschlich et al. C-reactive protein: a molecule composed of subunits.
BR9814473A (pt) Imunógenos anti-retrovirais, preparação e uso
Swann et al. The isolation and partial characterization of the major glycoprotein (LGP-I) from the articular lubricating fraction from bovine synovial fluid
BR0015137A (pt) Peptìdeos antigênicos de neisseria
BR9711457A (pt) Compostos e processo para o tratamento e diagnóstico de infecções micobacterianas.
BR0016066A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
BR0208874A (pt) Proteìnas superficiais de streptococcus pyogenes
BR9712298A (pt) Polipeptìdeo, molécula de dna, vetor de expressão recombinante, célula hospedeira, processo para detectar infecção por m. tuberculosis em uma amostra biológica, kit diagnóstico, anticorpos monoclonal, e, policlonal, e, proteìna de fusão
BR0112602A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
BR9809443A (pt) Polipeptìdeo compreendendo uma porção antigênica de um antìgeno de m. tuberculosis, molécula de dna, vetor recombinante de expressão, célula hospedeira, processo para detecção de infecção de m. tuberculosis em uma amostra biológica, kit de diganóstico, anticorpo monoclonal, anticorpo policlonal, e, proteìna de fusão.
BR0012069A (pt) Composições e métodos para a terapia e diagnóstico de câncer pulmonar
DE69333802T8 (de) Äusseres membranprotein von haemophilus
HUP0104717A2 (hu) Készítmények és eljárások petefészekrák terápiájára és diagnózisára
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
CA2377957C (fr) Derives citrullines de la fibrine et leur utilisation pour le diagnostic ou le traitement de la polyarthrite rhumatoide
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
BR9508467A (pt) Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
Klip et al. Alignment of the major tryptic fragments of the adenosine triphosphatase from sarcoplasmic reticulum.
BR0208041A (pt) Interferon beta modificado com imunogenicidade reduzida
BR9714133A (pt) ácido nucleico isolado, molécula do mesmo, sonda, vetor de expressão recombinante, célula, polipeptìdeo, proteìna de fusão formulação de vacina e processos para produzir um polipeptìdeo de h. pylori, para detctar a presença de um ácido nucleico de helicobacter em uma amostra, para tratar ou reduzir um risco de infecção por h. pylori em um indivìduo e para produzir uma formulação de vacina
BR0207015A (pt) Eritropoientina modificada (epo) com imunogenicidade reduzida

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]